Alnylam Pharmace. buy Oppenheimer Holdings Inc.
Start price
31.07.26
/
50%
€175.95
Target price
31.07.27
€304.08
Performance (%)
1.31%
Price
31.07.26
€178.25
Summary
This prediction is currently active. With a performance of 1.31%, the BUY prediction by Oppenheimer_Holdings for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 31.07.27. The prediction end date can be changed by Oppenheimer_Holdings at any time. Oppenheimer_Holdings has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | 1.31% |
| iShares Core DAX® | 2,59 % |
| iShares Nasdaq 100 | -0,91 % |
| iShares Nikkei 225® | 0,15 % |
| iShares S&P 500 | -0,37 % |
Comments by Oppenheimer_Holdings for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (ALNY) had its price target lowered by Oppenheimer Holdings, Inc. from $500.00 to $350.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Oppenheimer_Holdings for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€361.70
07.01.26
07.01.26
€427.30
07.01.27
07.01.27
-50.72%
31.07.26
31.07.26
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€359.70
04.08.25
04.08.25
€423.31
04.08.26
04.08.26
-50.44%
31.07.26
31.07.26